Applying a probability threshold of 25%, the MALAT-1-based model would prevent 30.2%-46.5% of unnecessary biopsies in the PSA 4–10 ng/ml cohort, while no high-grade cancers would be missed. This evidence concerns the gene KLK3 and cancer.